DeepMatter, the Glasgow-based scientific software firm which last week struck a deal with drugs giant AstraZeneca , has recruited three industry heavyweights as advisors as it looks to commercialise its technology
The company, which has developed a platform which enables chemistry experiments to be recorded and entered into a shared data cloud to enable scientists to work together, said the three appointments will play an important role in the roll-out of its technology.
The appointments include Dr Richard Bourne, associate Professor at the University of Leeds based at the Institute of Process Research and Development and pharmaceutical industry consultant Dr John Harris. Synthetic chemist Dr David Parry, who built and ran a business focused on automated medicinal chemistry, also joins.
Mark Warne, chief executive officer of DeepMatter, said each of the experts will bring valuable insight from their three areas of specialism, adding: “Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform.”
Under the collaboration announced with AstraZeneca last week, the big pharma firm will use DeepMatter’s DigitalGlassware platform to help accelerate its drug development work. It is the second commercial partnership to be secured by DeepMatter for the platform since it was launched earlier this year.
